Letter: a promising Helicobacter pylori regimen ‐ vonoprazan‐based therapy

Hu, Yi; Lv, Nonghua

doi:10.1111/apt.17114

Cited by 7 publications

(9 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The crude eradication rate of VA dual therapy was 87.5% by intention-to-treat (ITT) analysis and 89.6% by per-protocol (PP) analysis ( 7 ). VA dual therapy is considered as a promising H. pylori regimen because of its high efficacy, low side effects, and avoidance of unnecessary antibiotic use ( 8 ). However, the efficacy and safety of VA dual therapy in other regions remain uncertain, thus requiring the regimen to be optimized.…”

Section: Introductionmentioning

confidence: 99%

Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study

Liu

et al. 2023

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

Background and aimWe previously reported that vonoprazan-amoxicillin (VA) dual therapy for 7 or 10 days is not satisfactorily efficacious for Helicobacter pylori (H. pylori) eradication. We aimed to explore the efficacy of VA dual therapy for 14 days as a first-line treatment for H. pylori infection.MethodsThis was a single center, prospective, open-labeled, randomized non-inferiority clinical study conducted in China. Treatment naïve H. pylori infected patients were randomized into two groups: 20 mg vonoprazan (VPZ) b.i.d. in combination with low-dose (1000 mg b.i.d.) or high-dose (1000 mg t.i.d) amoxicillin for 14 days. 13C-urea breath tests were used to access the cure rate at least 4 weeks after treatment.ResultsA total of 154 patients were assessed and 110 subjects were randomized. The eradication rate of VPZ with b.i.d. amoxicillin or t.i.d. amoxicillin for 14 days was 89.1% and 87.3% by intention-to-treat analysis, respectively, and 94.1% and 95.9% by per-protocol analysis, respectively. The eradication rate and incidence of adverse events were not different between the two groups.ConclusionVPZ with b.i.d. or t.i.d. amoxicillin for 14 days provides satisfactory efficacy as a first-line treatment for H. pylori infection in China.

show abstract

Section: Introductionmentioning

confidence: 99%

Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study

Liu

et al. 2023

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the US trial the proportion was calculated as at least 95% 30 . VA dual therapy if optimized has the potential advantages of high efficacy, safety, avoidance of unnecessary antibiotic use, and minimal impact on gut microbiota 31,32 . The experience with VA dual therapy so far suggests that it may need to be optimized in different regions before it can be widely used for H. pylori eradication.…”

Section: Discussionmentioning

confidence: 99%

Research trends on vonoprazan‐based therapy for Helicobacter pylori eradication: A bibliometric analysis from 2015 to 2023

Ouyang

et al. 2023

Helicobacter

Self Cite

View full text Add to dashboard Cite

BackgroundVonoprazan is an emerging option for the treatment of Helicobacter pylori infection. We aimed to assess the research trends and hotspots of vonoprazan‐based therapy for H. pylori eradication through bibliometric analysis.Materials and MethodsVonoprazan‐based studies for eradicating H. pylori published from 2015 to 2023 were extracted from the Web of Science using a combination of the search terms “H. pylori” and “vonoprazan.” Each study was weighted according to the number of included patients.ResultsA total of 65 studies were included. Japan was the most productive and cooperative country, accounting for 69.2% of publications. Vonoprazan in combination with amoxicillin and clarithromycin (41.8%) was most used for eradicating H. pylori, followed by vonoprazan in combination with amoxicillin (20.4%) and vonoprazan in combination with amoxicillin and metronidazole (19.4%). The eradication rates for first‐line vonoprazan‐based therapies by intention to treat were: dual therapy (82.9%, 95% CI: 77.7%–88.0%), triple (83.3%, 95% CI: 79.7%–86.8%) and quadruple therapy (91.5%, 95% CI: 85.5%–97.4%), and per protocol: dual therapy (86.1%, 95% CI: 81.5%–90.7%), triple (89.3%, 95% CI: 87.9%–90.6%) and quadruple therapy (94.0%, 95% CI: 88.6%–99.4%). Vonoprazan was superior to proton pump inhibitors in triple therapy regarding empirical therapy (RR = 1.18, 95% CI, 1.14–1.22, p < 0.01) and clarithromycin‐resistant group (RR = 1.71, 95% CI, 1.33–2.20, p < 0.01), but there is no significant difference between triple therapy and dual therapy (RR = 1.02, 95% CI, 0.98–1.07, p = 0.33).ConclusionsVonoprazan has been widely used for H. pylori eradication. Further studies are needed to optimize the best duration and dosage of vonoprazan‐based regimens in different regions.

show abstract

“…H. pylori eradication could increase the alpha diversity indexes, decrease the microbial interactions, alter microbial community structure and microbial community structures in short-term and long-term follow-ups, which was supported by a systematic review and meta-analysis by Guo et al It is still controversial regarding whether H. pylori eradication could restore gastric microbiota to uninfected status. Vonoprazan-amoxycillin (VA) dual therapy is a promising H. pylori regimen because of its high efficacy, safety and the avoidance of unnecessary antibiotics use (Hu and Lu, 2022). Hu et al further demonstrated that the alteration of the gut microbiota induced by the VA dual therapy was restored at the confirmation time point (1 month after eradication), which indicated that the VA dual therapy has minimal negative effects on the gut microbiota.…”

Section: H Pylori Pathogenesismentioning

confidence: 99%

“…It is still controversial regarding whether H. pylori eradication could restore gastric microbiota to uninfected status. Vonoprazan- amoxycillin (VA) dual therapy is a promising H. pylori regimen because of its high efficacy, safety and the avoidance of unnecessary antibiotics use ( Hu and Lu, 2022 ). Hu et al.…”

Section: The Influence Of H Pylori Infection or Er...mentioning

confidence: 99%

Editorial: The interactions between gastrointestinal microbiota and Helicobacter pylori in diseases

Zhuang²,

Gou³

et al. 2022

Front. Cell. Infect. Microbiol.

Self Cite

View full text Add to dashboard Cite

Editorial on the Research TopicThe interactions between gastrointestinal microbiota and Helicobacter pylori in diseases Helicobacter pylori (H. pylori) is a medically important pathogen colonizing the stomach, leading to the damage of gastric mucosa from chronic active gastritis, chronic atrophic gastritis, intestinal metaplasia and dysplasia to intestinal-type gastric cancer (GC) in a subset of infected subjects (Correa, 2013). H. pylori was defined as a carcinogen by the World Health Organization in 1994 and the U.S. Department of Health and Human Services in 2021. According to Maastricht VI/Florence consensus report, H. pylori infection is a primary cause for the development of GC, and H. pylori eradication prior to the stage of chronic atrophic gastritis is the most effective for the prevention of GC (Malfertheiner et al., 2022). It has been documented that the occurrence of spontaneous atrophic gastritis and gastrointestinal intraepithelial neoplasia (GIN) was not developed in germ-free (GF) transgenic insulin-gastrin (INS-GAS) mice by 13 months of age. However, H. pylori infection accelerated the development of GIN in GF INS-GAS mice, which was noted by 9 to 11 months post-H. pylori infection (equivalent to 11 to 13 months of mouse age). Comparing with H. pylori-infected INS-GAS mice with the complex gastric microbiota, H. pylori monoassociation caused less severe gastric lesions and delayed onset of GIN (Lofgren et al., 2011). In human patients, a distinct cluster of oral bacteria (Peptostreptococcus etc.) were associated with emergence and persistence of atrophy and intestinal metaplasia in subjects who developed atrophy 1 year after H. pylori eradication (Sung et al., 2020), which indicated that other organisms might be also involved in gastric inflammation and gastric carcinogenesis.

show abstract

Letter: a promising Helicobacter pylori regimen ‐ vonoprazan‐based therapy

Abstract: LINKED CONTENT This article is linked to Ang et al papers. To view these articles, visit https://doi.org/10.1111/apt.17070 and https://doi.org/10.1111/apt.17133

Cited by 7 publications

References 10 publications

Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study

Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study

Research trends on vonoprazan‐based therapy for Helicobacter pylori eradication: A bibliometric analysis from 2015 to 2023

Editorial: The interactions between gastrointestinal microbiota and Helicobacter pylori in diseases

Contact Info

Product

Resources

About